Evidence Level:Sensitive: A2 - Guideline
New
Excerpt:Esophageal and Esophagogastric Junction Cancers: HER2 overexpression negative…Fluoropyrimidine (fluorouracil or capecitabine) and oxaliplatin…
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors
Excerpt:...： Patients with at least one measurable lesion per RECIST (v1.1); Patients with medium or high expression of Claudin18.2 in tumor tissue samples tested by immunohistochemistry in central laboratory were included; Patients with untreated, unresectable advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with negative HER-2 immunohistochemistry or FISH test (HER-2 immunohistochemistry 0/1+ confirmed by a qualified local or central laboratory, or 2+ confirmed negative by FISH test) were included; Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 at screening and...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Prospective, Multicenter Clinical Study of the Efficacy and Safety of First-Line Treatment with Ivonescimab in Combination with XELOX for Unresectable Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Excerpt:...HER-2 negative; 5. ...
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Study on the treatment of patients with gastroesophageal cancer with chemotherapy and immunotherapy based on a non-functioning DNA mismatch repair mechanism in the tumour cells Onderzoek naar de behandeling van patiënten met maag-/slokdarmkanker met chemotherapie en immunotherapie op basis van een niet werkend DNA mismatch herstel mechanisme in de tumorcellen
Excerpt:...- Male or female adult patients (> 18 years)- Primaire tumor or metastasis accessible for repeat fresh histological biopsies- dMMR identified by IHC of mismatch repair proteins MLH1, PMS2, MSH2, and MSH6- Patients with histologically confirmed diagnosis of metastatic or irresectable HER2 negative adenocarcinoma of the stomach or oesophagus; patients with HER2 positive disease are eligble when treatment with trastuzumab is contraindicated. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study
Excerpt:...Is confirmed by histopathology and/or cytology her2-negative or HER2 status unknown late recurrence or stomach esophagus stomach/integration of adenocarcinoma; 4....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
Excerpt:...- Patients with histologically confirmed diagnosis of metastatic or irresectable HER2 negative adenocarcinoma of the stomach or gastroesophageal junction (Siewert II and III); patients with HER2 positive disease are eligible when treatment with trastuzumab is contraindicated....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Multicenter, Open-Label, Single-Arm Phase II Trial to Evaluate the Efficacy and Safety of Capecitabine /Oxaliplatin (XELOX Regimen) in Combination with Regorafenib and PD-1 Monoclonal Antibody in First-line Treatment of Patients with HER2-negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
